Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Income from Continuing Operations (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Income from Continuing Operations for 11 consecutive years, with 27426000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 20.47% to 27426000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 119721000.0 through Dec 2025, down 84.18% year-over-year, with the annual reading at 119721000.0 for FY2025, 84.18% down from the prior year.
  • Income from Continuing Operations hit 27426000.0 in Q4 2025 for Voyager Therapeutics, up from 27892000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 124044000.0 in Q1 2023 to a low of 34487000.0 in Q4 2024.
  • Historically, Income from Continuing Operations has averaged 8642900.0 across 5 years, with a median of 22909000.0 in 2022.
  • Biggest five-year swings in Income from Continuing Operations: crashed 566.69% in 2022 and later surged 681.85% in 2023.
  • Year by year, Income from Continuing Operations stood at 5059000.0 in 2021, then plummeted by 566.69% to 23610000.0 in 2022, then surged by 338.86% to 56395000.0 in 2023, then tumbled by 161.15% to 34487000.0 in 2024, then rose by 20.47% to 27426000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for VYGR at 27426000.0 in Q4 2025, 27892000.0 in Q3 2025, and 33382000.0 in Q2 2025.